Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease

European Journal of Neurology

Volumn 10, Issue 4, 2003, Pages 391-398

  Schaafsma, J D ^a   Balash, Y ^a   Gurevich, T ^a   Bartels, A L ^a   Hausdorff, J M ^a,b   Giladi, Nir ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Freezing of gait; Parkinson's disease; Paroxysmal gait disturbances

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; AKINESIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; DRUG RESPONSE; FEMALE; FRIEDMAN TEST; GAIT; GAIT DISORDER; HUMAN; LEG; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANK SUM TEST; VIDEORECORDING; CLASSIFICATION; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MOTION; NEUROLOGIC DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; REGRESSION ANALYSIS; REPRODUCIBILITY; TIME;

AGED; ANTIPARKINSON AGENTS; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; LEG; LEVODOPA; MALE; MIDDLE AGED; MOTION; PARKINSONIAN DISORDERS; PREVALENCE; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; VIDEOTAPE RECORDING;

EID: 0041784764     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00611.x     Document Type: Article

References (28)

1. Ahlskog JE, Muenter MD, Bailey PA, Stevens PM (1992). Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide). Arch Neurol 49:560-568.
2. Ambani LM, Van Woert MH (1973). Start hesitation - a side effect of long-term levodopa therapy. N Engl J Med 288:1113-1115.
3. Andrews CJ (1973). Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 36:630-636.
4. Armitage P, Berry G (1994). Statistical Methods in Medicine Research, 3rd edn. Blackwell Scientific Publications, Oxford.
5. Arnt J, Bogeso KP, Hyttel J, Meier E (1988). Relative dopamine D1 and D2 receptors affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol Toxicol 62:121-130.
6. Corboy DL, Wagner ML, Sage JI (1995). Apomorphine for motor fluctuations and freezing in PD. Ann Pharmacother 29:282-287.
7. Denny AP, Behari M (1999). Motor fluctuations in Parkinson's disease. J Neurol Sci 165:18-23.
8. Fahn S. (1995). The freezing phenomenon in Parkinsonism. In: Fahn S, Hallett M, Luders HO, Marsden CD, eds. Negative Motor Phenomena. Advances in Neurology, Vol. 67. Lippincott-Raven Publishers, Philadelphia, pp. 53-63.
9. Fahn S, Elton RL and members of the UPDRS Developmental Committee (1987). Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ. Macmillan Healthcare Information 1987, pp. 153-163, 293-304.
10. Gelb DJ, Oliver E, Gilmans S (1999). Diagnostic criteria for PD. Arch Neurol 56:33-39.
11. Giladi N, McMahon D, Przedborski S et al. (1992). Motor blocks in Parkinson's disease. Neurology 42:333-339.
12. Giladi N, Kao R, Fahn S (1997). Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 12:302-305.
13. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD (2000). Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 6:165-170.
14. Giladi N, Gurevich T, Paleacu D, Shabtai H, Simon S (2001a). Treatment of parkinsonian freezing of gait with botulinum toxin injections to the calf muscles. J Neurol 248:572-576.
15. Giladi N, McDermott MP, Fahn S et al. (2001b). DATATOP: freezing of gait in Parkinson's disease - prospective assessment in the DATATOP cohort. Neurology 56:1712-1721.
16. Giladi N, Treves TA, Simon ES et al. (2001e). Freezing of gait in patients with advanced Parkinson's disease. J Neurol Transm 108:53-61.
17. Giladi N, Balash Y, Hausdorff JM (2002). Gait disturbances in Parkinson's disease. In: Mizuno Y, Fisher A, Hanin I, eds. Mapping the Progress of Alzheimer's and Parkinson's Disease. Kluwer Academic/Plenum Publishers, New York, pp. 329-335.
18. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
19. Lamberti P, Armenise S, Castaldo V et al. (1997). Freezing gait in Parkinson's Disease. Eur Neurol 38:297-301.
20. Narabayashi H (1985). Akinesia in parkinsonism. Pharmacological and physiological analysis. In: Struppler A, Weindl A, eds. Electromyography and Evoked Potentials. Springer-Verlag, Berlin, pp. 30-34.
21. Narabayashi H, Nakamura R (1985b). Clinical neurophysiology of freezing in Parkinsonism. In: Delwaide PJ, Agnoli A, eds. Clinical Neurophysiology in Parkinsonism. Elsevier, Amsterdam, pp. 49-57.
22. Parkinson Study Group (2000). Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 18:284:1931-1938.
23. Rascol O, Brooks DJ, Korczyn AD et al. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491.
24. Shoulson I, Oakes D, Fahn S et al. (2002). Impact of sustained Deprenyl (Selegeline) in Levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the Tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 5l:604-612.
25. Shrout PE, Fleiss JL (1979). Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420-428.
26. Thompson PD, Marsden CD (1995). Walking disorders. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice - Principles of Diagnosis and Management. Butterworth-Heinemann, Boston, pp. 321-334.
27. Ueno E, Yanagisawa N, Takami M (1993). Gait disorders in parkinsonism. A study with floor reaction forces and EMG. Adv Neurol 60:414-418
28. Wiener WJ, Factor SA, Sanches-Ramos JR et al. (1993). Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 43:21-27.